CN102421763B - 含有寡聚体的取代的芳族三嗪化合物 - Google Patents

含有寡聚体的取代的芳族三嗪化合物 Download PDF

Info

Publication number
CN102421763B
CN102421763B CN201080020581.5A CN201080020581A CN102421763B CN 102421763 B CN102421763 B CN 102421763B CN 201080020581 A CN201080020581 A CN 201080020581A CN 102421763 B CN102421763 B CN 102421763B
Authority
CN
China
Prior art keywords
oligomer
group
alkyl
compound
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080020581.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102421763A (zh
Inventor
J·里吉斯-索希尔
邓波良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of CN102421763A publication Critical patent/CN102421763A/zh
Application granted granted Critical
Publication of CN102421763B publication Critical patent/CN102421763B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080020581.5A 2009-05-13 2010-05-13 含有寡聚体的取代的芳族三嗪化合物 Active CN102421763B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17793109P 2009-05-13 2009-05-13
US61/177,931 2009-05-13
PCT/US2010/034770 WO2010132691A1 (en) 2009-05-13 2010-05-13 Oligomer-containing substituted aromatic triazine compounds

Publications (2)

Publication Number Publication Date
CN102421763A CN102421763A (zh) 2012-04-18
CN102421763B true CN102421763B (zh) 2015-06-17

Family

ID=42557491

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080020581.5A Active CN102421763B (zh) 2009-05-13 2010-05-13 含有寡聚体的取代的芳族三嗪化合物

Country Status (10)

Country Link
US (4) US8772479B2 (enExample)
EP (1) EP2430003B1 (enExample)
JP (1) JP5656980B2 (enExample)
KR (1) KR101799113B1 (enExample)
CN (1) CN102421763B (enExample)
AU (1) AU2010248943B2 (enExample)
CA (1) CA2760219C (enExample)
IL (1) IL216314B (enExample)
MX (1) MX2011012044A (enExample)
WO (1) WO2010132691A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011012044A (es) 2009-05-13 2011-12-14 Nektar Therapeutics Compuestos de triazina aromatica sustituida que contienen oligomeros.
WO2015092819A2 (en) * 2013-12-21 2015-06-25 Nektar Therapeutics (India) Pvt. Ltd. Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine
JP6884703B2 (ja) 2015-02-25 2021-06-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 障害を治療するための５ｈｔ作動薬

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE49823B1 (en) 1979-06-01 1985-12-25 Wellcome Found 1,2,4-triazine derivatives,process for preparing such compounds and pharmaceutical compositions containing them
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5028703A (en) 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
JP2004514701A (ja) * 2000-11-30 2004-05-20 ネクター　セラピューティクス　エーエル，コーポレイション トリアジン誘導体の水溶性ポリマー複合体
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
RS53279B (sr) 2003-12-16 2014-08-29 Nektar Therapeutics Monodisperzne smeše pegilisanog naloksola
FR2869907B1 (fr) 2004-05-05 2009-02-13 Fabre Pierre Dermo Cosmetique Derives dimeriques de 5,6-diphenyl-1,2,4-triazine et leurs utilisations
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
MX2007002210A (es) * 2004-08-26 2007-05-07 Nicholas Piramal India Ltd Profarmacos que contienen enlazantes bioescindibles novedosos.
US7678551B2 (en) 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US20060115865A1 (en) 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs
US20080044438A1 (en) 2006-03-17 2008-02-21 Ostroff Gary R Yeast Cell Particles As Oral Delivery Vehicles For Antigens
MX2011012044A (es) 2009-05-13 2011-12-14 Nektar Therapeutics Compuestos de triazina aromatica sustituida que contienen oligomeros.

Also Published As

Publication number Publication date
EP2430003A1 (en) 2012-03-21
KR20120015311A (ko) 2012-02-21
US20140256732A1 (en) 2014-09-11
CA2760219C (en) 2016-08-16
US20150065706A1 (en) 2015-03-05
CA2760219A1 (en) 2010-11-18
AU2010248943B2 (en) 2015-05-21
IL216314A0 (en) 2012-01-31
MX2011012044A (es) 2011-12-14
EP2430003B1 (en) 2019-02-27
US9266845B2 (en) 2016-02-23
JP5656980B2 (ja) 2015-01-21
AU2010248943A1 (en) 2011-11-10
US20160194294A1 (en) 2016-07-07
IL216314B (en) 2018-05-31
CN102421763A (zh) 2012-04-18
US9617228B2 (en) 2017-04-11
KR101799113B1 (ko) 2017-11-17
US8772479B2 (en) 2014-07-08
JP2012526847A (ja) 2012-11-01
US8895553B2 (en) 2014-11-25
US20120122871A1 (en) 2012-05-17
WO2010132691A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
CN101631569B (zh) 低聚物-抗组胺剂偶联物
CN102421763B (zh) 含有寡聚体的取代的芳族三嗪化合物
WO2010120386A1 (en) Oligomer-protein tyrosine kinase inhibitor conjugates
US9399033B2 (en) Oligomer-containing pyrrolidine compounds
CN102300588A (zh) 低聚物-吩噻嗪缀合物
US9421204B2 (en) Oligomer modified diaromatic substituted compounds
CN105566284A (zh) 低聚物-芳氧基-取代的丙胺共轭物
EP2627639A1 (en) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides
Zhang et al. Synthesis of poly (ethylene glycol)–metaxalone conjugates and study of its controlled release in vitro
López-Méndez et al. β-cyclodextrin dendritic derivatives as permeation mediators to enhance the in vitro albendazole cysticidal activity by the improvement of the diffusion component
EP2400989B1 (en) Gabapentin-peg conjugates
US9540330B2 (en) Oligomer-containing hydantoin compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant